Combined use of phenoxybenzamine and dopamine for low cardiac output syndrome in children at withdrawal from cardiopulmonary bypass

MITSUO KAWAMURA, OSAMU MINAMIKAWA, HIROSHI YOKOCHI, SHIGEO MAKI, TAKASHI YASUDA, YUTAKA MIZUKAWA

From the Department of Cardiovascular Surgery, Meijyo Hospital, Nagoya, Japan

SUMMARY The combined use of phenoxybenzamine and dopamine was applied in infants and children when it was difficult to come off cardiopulmonary bypass for low cardiac output. The rationale of this method is to prevent the alpha-adrenergic action of dopamine by phenoxybenzamine and to encourage the beta-adrenergic and direct specific action of dopamine. Dopamine was used in dosage of 10 to 30 μg/kg per min after the additional administration of a half of the initial dosage of phenoxybenzamine; this was infused by drip always in a dosage of 0.5 to 1.0 mg/kg during the first half of cardiopulmonary bypass.

It was possible to come off cardiopulmonary bypass with a stable haemodynamic state (mean arterial pressure more than 60 mmHg and total peripheral vascular resistance less than 2000 dynes s cm⁻²) and a good urinary output.

Dopamine is a biochemical precursor of norepinephrine which increases myocardial contractile force by a beta-adrenergic action and produces mild vasoconstriction by an alpha-adrenergic action. It also produces renal and mesenteric vasodilatation by a direct specific action, not antagonised by either alpha- or beta-adrenergic blocking agents. This unique combination of properties provides a rational basis for the use of dopamine in the treatment of cardiogenic shock.

The combined use of dopamine and phenoxybenzamine, an alpha-adrenergic blocking agent, was attempted in the treatment of low cardiac output syndrome in patients coming off cardiopulmonary bypass.

Subjects and methods

Studies were made on 27 patients (age range 8 months to 6 years and 8 months) with congenital heart disease, who underwent open-heart surgery at Meijyo Hospital from July 1977 to June 1978 (Table 1). The combined use of phenoxybenzamine and dopamine was attempted in nine patients where difficulty had occurred in attempting to come off cardiopulmonary bypass. The other 18 patients, in whom phenoxybenzamine only was used, were studied as controls (Table 2).

Cardiopulmonary bypass was accomplished with a small roller pump arranged for paediatric perfusion and a Temptral oxygenator designed for infants. The haemodilution ratio was 35 to 45 per cent using the normothermic method and 20 to 35 per cent using the hypothermic method. The perfusion flow was checked and controlled every 15 minutes during cardiopulmonary bypass in order to maintain optimum perfusion. It resulted in a perfusion index of 3·4 to 3·91/min per kg at 15 minutes of bypass at which time the haemoglobin concentration showed the minimum value. Total circulatory arrest within 30 minutes was applied when the oesophageal temperature was 20°C (Table 2). The practice of administration of phenoxybenzamine and dopamine is as follows. Phenoxybenzamine was infused by drip into an oxygenator at a dosage of 0.5 to 1.0 mg/kg within the first half of cardiopulmonary bypass in all cases of this series. Whenever dopamine was necessary in the cases in which it was difficult to come off cardiopulmonary bypass, dopamine 10 to 30 μg/kg per min was given after the additional administration of half the initial dose of phenoxybenzamine and was gradually reduced.

Arterial pressure (AP), central venous pressure (CVP), perfusion flow, urinary output, body temperature, electrocardiogram, and electroencephalogram were monitored continuously. Blood gas analysis, acid-base status, electrolyte balance,
haemoglobin, and free haemoglobin values were measured at 15-minute intervals during cardiopulmonary bypass. The perfusion index (PI) and total peripheral vascular resistance (TPVR) were calculated using the following formula:

\[ \text{TPVR (dynes s cm}^{-5} ) = \frac{[\text{AP} - \text{CVP} \text{ (mmHg)}]}{1332} \times 60 \]

Perfusion flow (ml/min)

* 1332 is the factor to convert mmHg to dynes/cm². Results are expressed as mean ± SD.

### Results

**NORMOTHERMIC GROUP**

Arterial oxygen tension was 238 ±51 mmHg and carbon dioxide tension was 40 ±8 mmHg. Arterio-

venous difference in oxygen saturation was from 30 to 40 per cent and pH value in arterial and venous blood was 7.4 ±0.05 during cardiopulmonary bypass. Mean arterial pressure was maintained above 60 mmHg. However, total peripheral vascular resistance gradually increased with the lapse of perfusion time and in these circumstances administration of phenoxybenzamine was effective in reducing it. But in seven cases in this group where an effective cardiac output could not be achieved after repair of the cardiac anomalies, temporary assisted circulation with the administration of dopamine was instituted. The total peripheral vascular resistance in these patients during administration of dopamine at a constant rate (10 to 30 µg/kg per min) did not increase compared with the patients using phenoxybenzamine only, and they could come off cardiopulmonary bypass in a stable haemodynamic condition (Table 3).

Fig. 1 shows the course of a girl of 4 years and 5 months weighing 18 kg who had an endocardial cushion defect and mitral regurgitation. The ostium primum defect was closed with a pericardial patch and the mitral cleft was repaired by two U-stay sutures. As soon as cardiopulmonary bypass was stopped, she lapsed into low cardiac output, with mean arterial pressure 30 mmHg, central venous pressure 28 cm H₂O, and anuria. Low flow-assisted circulation was carried out twice with the combined use of phenoxybenzamine and dopamine. As a result, effective cardiac output and good urinary output were obtained, and she could be taken off assisted circulation.

**HYPOTHERMIC GROUP**

The method of deep hypothermia combined with cardiopulmonary bypass was applied in six severe cases whose body weight was about 10 kg. Complete circulatory arrest or extremely low flow perfusion was used in order to make intracardiac operation easier with an oesophageal temperature of 15 to 25°C.

### Table 1 Patient population

<table>
<thead>
<tr>
<th>Patient population</th>
<th>Normothermia</th>
<th>Hypothermia</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Normal</td>
<td>Hypothermia</td>
</tr>
<tr>
<td>TOF</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PDA</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>ASD</td>
<td>6</td>
<td>2</td>
</tr>
<tr>
<td>VSD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>+PS + AR</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>+ MR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>+ TCRV</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ECD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>+ ASD + PS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>+ MR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>14</td>
<td>7</td>
</tr>
</tbody>
</table>

POB, phenoxybenzamine; DA, dopamine; TOF, tetralogy of Fallot; PDA, persistent ductus arteriosus; VSD, ventricular septal defect; ASD, atrial septal defect; PS, pulmonary stenosis; AR, aortic regurgitation; MR, mitral regurgitation; TCRV, two-chambered right ventricle; ECD, endocardial cushion defect.

* After Blalock's operation.

### Table 2 Method of cardiopulmonary bypass

<table>
<thead>
<tr>
<th>No. of patients</th>
<th>Body weight (kg)</th>
<th>BSA (m²)</th>
<th>Haemodilution ratio (%)</th>
<th>Perfusion index (l/min per cent)</th>
<th>Total perfusion time (min)</th>
<th>Minimum body temperature (°C)</th>
<th>Oesophageal</th>
<th>Rectal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normothermia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>POB</td>
<td>14</td>
<td>12.2 ±3.2</td>
<td>0.55 ±0.12</td>
<td>44.5 ±10.9</td>
<td>3.9 ±0.5</td>
<td>102.2 ±28.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>POB + DA</td>
<td>7</td>
<td>13.7 ±4.0</td>
<td>0.59 ±0.16</td>
<td>34.7 ±7.3</td>
<td>3.7 ±0.4</td>
<td>105.7 ±21.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypothermia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>POB</td>
<td>4</td>
<td>10.5 ±3.4</td>
<td>0.46 ±0.15</td>
<td>35.4 ±13.9</td>
<td>3.4 ±0.7</td>
<td>142.0 ±63.2</td>
<td>19.1 ±5.3</td>
<td>21.8 ±5.3</td>
</tr>
<tr>
<td>POB + DA</td>
<td>2</td>
<td>8.6 ±2.7</td>
<td>0.41 ±0.08</td>
<td>21.5 ±2.7</td>
<td>3.5 ±2.7</td>
<td>123.5 ±59.5</td>
<td>24.0 ±2.6</td>
<td>26.2 ±0.9</td>
</tr>
</tbody>
</table>

POB, phenoxybenzamine; DA, dopamine; BSA, body surface area.
Total peripheral vascular resistance increased gradually in proportion to the decrease in blood pressure and body temperature, to about 200 or 300 per cent of normal at 30 minutes of bypass. This returned to about 2000 dynes cm⁻² at the time of withdrawal from cardiopulmonary bypass by rewarming and administering phenoxybenzamine. In two patients in this group, however, cardiogenic shock with high total pulmonary vascular resistance and oliguria occurred immediately after cardiopulmonary bypass was stopped, and assisted circulation was carried out with a drip infusion of dopamine at a constant rate (30 µg/kg per min) after the additional administration of phenoxybenzamine (0.5 to 1.0 mg/kg). Assisted circulation for a short time produced sufficient arterial pressure and urinary output, with lowering of total peripheral vascular resistance, for these patients to come off cardiopulmonary bypass (Table 4).

Fig. 2 shows the course of a boy of 19 months (6.7 kg in body weight) with ventricular septal defect, persistent ductus arteriosus, severe pulmonary hypertension, and left superior vena cava. The ductus arteriosus was closed by suture ligation under total circulatory arrest combined with deep hypothermia at an oesophageal temperature of 19°C, and the ventricular septal defect was closed by U-stay suture with a Teflon patch. Phenoxybenzamine was used in a dosage of 0.5 mg/kg at the time of bypass rewarming. As the arterial pressurer decreased gradually and the central venous pressure increased when cardiopulmonary bypass was withdrawn, assisted circulation with the combined use of phenoxybenzamine and dopamine was required for 31 minutes in order to prevent low cardiac output syndrome.

Discussion

During cardiopulmonary bypass a patient is considered to be in a state of pre-shock with a moderate increase in systemic vascular resistance. To combat this, many kinds of vasodilators are used during cardiopulmonary bypass and catecholamines are given frequently after bypass. Among

---

Table 3  Serial changes of total peripheral vascular resistance during cardiopulmonary bypass with normothermia

<table>
<thead>
<tr>
<th>Cardiopulmonary bypass</th>
<th>15 min</th>
<th>30 min</th>
<th>60 min</th>
<th>120 min</th>
<th>120 to 210 min</th>
</tr>
</thead>
<tbody>
<tr>
<td>POB</td>
<td>1749±00 (n=14)</td>
<td>2248±94 (n=14)</td>
<td>2432±83 (n=6)</td>
<td>2141±25 (n=7)</td>
<td>2144±57 (n=4)</td>
</tr>
<tr>
<td>POB + DA</td>
<td>1843±43 (n=7)</td>
<td>2180±14 (n=7)</td>
<td>1696±51 (n=7)</td>
<td>2141±25 (n=7)</td>
<td>2144±57 (n=4)</td>
</tr>
</tbody>
</table>

POB, phenoxybenzamine; DA, dopamine.

* After drip infusion of 0.5 to 1.0 mg/kg phenoxybenzamine.
† During drip infusion of 10 to 30 µg/kg per min dopamine after additional infusion of 0.5 to 1.0 mg/kg phenoxybenzamine.

---

Fig. 1  Haemodynamic changes during study period of patient HN.
these drugs, it may be appropriate to use phenoxybenzamine or isoprenaline and dopamine.

Isoprenaline produces cardiac stimulation and mesenteric and peripheral vasodilatation by its action on the beta-adrenergic receptors. Currently, it occupies a position of prominence in the treatment of shock syndrome unresponsive to volume expansion, regardless of aetiology. On the other hand, phenoxybenzamine is known to increase the cardiac output, stroke volume, and renal blood flow when given intravenously. Alpha-adrenergic receptor blocking drugs such as phenoxybenzamine induce cardiac stimulation mostly because the fall in systemic blood pressure accompanying systemic vasodilatation initiates reflex tachycardia. Because isoprenaline increases heart rate and causes arrhythmia much more often than does phenoxybenzamine, we combined phenoxybenzamine with dopamine in patients in the low cardiac output state at the time of withdrawal of cardiopulmonary bypass.

Many experimental reports have indicated that low doses of dopamine decrease resistance in the renal and mesenteric vascular beds, but not in the limb circulation, and that higher doses cause predominant vasoconstriction in both visceral and limb vascular beds. In addition, many clinical studies indicated that, in adults, low doses (2 to 5 μg/kg per min) caused increased renal blood flow with little effect on heart rate, blood pressure, or myocardial contractility; moderate doses (5 to 15 μg/kg per min) caused increased renal blood flow, heart rate, cardiac contractility, and cardiac output; and high doses (more than 20 μg/kg per min) produced a renal blood flow which might be reduced. In infants and children, dopamine is a safe drug when used in moderate doses and is effective in increasing blood pressure and urine production with little change in heart rate and central venous pressure. This unique mechanism responsible for the direct vasodilator effect is believed to be specific to the mesenteric and renal bed. Furthermore, dopamine increases coronary artery blood flow but with relatively less increase in myocardial oxygen consumption and, therefore, increases myocardial efficiency. The dose of dopamine (30 μg/kg per min) used in this series is high by the above criteria. But as the circulatory blood volume of the patient increased about two-fold during cardiopulmonary bypass in which whole blood and diluent (800 to 1500 ml) were primed into oxygenator and extracorporeal circuit, the actual dose of dopamine was considered to be moderate (about 15 μg/kg per min). The combined use of phenoxybenzamine and dopamine provided a stable haemodynamic condition without a high total peripheral vascular resistance and stimulated the removal of diluent by good urinary output.

This method is useful in the treatment of the low cardiac output syndrome when coming off cardiopulmonary bypass.
References

3Eble JN. A proposed mechanism of the depressor effect of dopamine in the anesthetized dog. *J Pharmacol Exp Ther* 1964; 145: 64-70.

Requests for reprints to Dr Mitsuo Kawamura, 7-7 Uchida Higashi-machi, Inuyama-shi, Aichi-ken 484, Japan.